Centralized eTMF management for multiple concurrent studies.
TL;DR: A centralized eTMF supports multiple concurrent studies by giving every trial the same document structure (typically aligned to the TMF Reference Model), one shared set of user permissions and audit trails across the portfolio, and a single reporting layer that shows completeness study-by-study and across the pipeline. The alternative — a separate eTMF instance, or a shared drive, per study — multiplies setup work and audit risk every time a new trial starts.
Centralized eTMF management means one system holds the Trial Master File for every active study, using the same document taxonomy, the same permission model, and the same audit trail mechanism — rather than each trial getting its own instance, folder structure, or vendor relationship.
In practice, that comes down to four things working the same way across every study in the portfolio:
A per-study or shared-drive approach breaks down once a second or third concurrent trial starts, because the shortcuts that worked fine for one program begin compounding: duplicate setup work, inconsistent cross-study reporting, and permission sprawl. A single-study biotech can often get by with a shared drive, a spreadsheet tracker, or even a CRO-managed instance dedicated to that one trial — the trouble is what happens next.
Three failure patterns show up consistently as a portfolio grows:
None of these are dramatic failures on their own. They accumulate quietly, and the bill usually comes due at the least convenient moment — a regulatory inspection that spans multiple active trials at once.
A system built for a single study and a system built to manage several concurrent studies well are not the same product, even if they share a feature list on paper. The difference shows up in five specific capabilities.
The industry-standard reference for this is the DIA TMF Reference Model, which groups trial documents into 11 defined zones — Trial Management, Central Trial Documents, Regulatory, IRB/IEC and Other Approvals, Site Management, Investigational Product and Trial Supplies, Safety Reporting, Centralized and Local Testing, Third Parties, Data Management, and Statistics.[1] A centralized eTMF applies this same zone structure to every study by default, so a new trial doesn't require reinventing a filing scheme — it inherits one.
Rather than provisioning access per study, a centralized system defines roles once — CRA, site coordinator, sponsor reviewer, inspector — and applies them across whichever studies a given person actually needs. When someone's role changes or a study closes, access can be revoked in one place instead of tracked down across several.
Regulators increasingly expect sponsors to demonstrate that a trial's electronic records stay electronic and traceable throughout their lifecycle, not reconstructed after the fact for an inspection.[2] A dashboard that shows document completeness and aging across every active study — not just the one currently being audited — is what makes that demonstrable on demand rather than assembled under deadline pressure. This kind of automated, cross-study indexing is also what makes documents in each study genuinely findable and audit-ready as the TMF grows, rather than just filed.
ICH E6(R3), the current Good Clinical Practice guideline, extends its computerized-systems expectations to how records are controlled and traced throughout a trial, treating access controls and an intact audit history as baseline requirements rather than optional hardening.[3] A centralized eTMF applies that same, single audit trail mechanism to every study, so an inspector reviewing two or three trials at once sees one consistent logging standard instead of three.
The real test of a centralized system is what happens when study four starts while studies one through three are still active. Onboarding a new trial should mean applying an existing template and role set — not standing up a parallel structure from scratch. This is also where the business case sharpens: the global clinical trials market is on pace to grow from roughly $94.0 billion in 2026 to $158.4 billion by 2033 (a 7.7% CAGR),[4] and a growing share of that growth is concentrated in smaller, faster-moving sponsors running several trials in parallel rather than one at a time — exactly the profile where onboarding friction compounds fastest.
The comparison below reflects three general approaches life sciences teams take as they move from one study to several, not a ranked or exhaustive list — the right fit depends on portfolio size, team structure, and how many studies are actually running at once. Readers should validate any of these against their own requirements before deciding.
| Criteria | Separate eTMF instance per study | Shared drives or a generic DMS across studies | One centralized eTMF platform |
|---|---|---|---|
| Setup time for a new study | Repeated in full for every trial | Fast to start, but structure is usually improvised each time | Fast — new study inherits existing structure and roles |
| Consistency of document structure | Varies by instance and by whoever configured it | Inconsistent by default; depends on manual discipline | Uniform across every study |
| Cross-study reporting | Requires manually reconciling each instance | Not natively supported | Native, portfolio-level view |
| Audit trail continuity | Separate trail per instance | Limited or no formal audit trail | One continuous, consistent audit trail |
| Permission management as the portfolio grows | Reconfigured per instance for every reviewer | Often managed informally via folder permissions | Defined once, applied across studies |
| Best fit for | A single active study, or studies that must stay contractually isolated (e.g., different CRO-managed instances) | Very early-stage teams before their first study reaches meaningful document volume | Sponsors running two or more concurrent studies who need one consistent compliance story |
Kivo's eTMF module is built on the same document core, permissioning model, and audit trail that also power Kivo's RIM and QMS modules — so a centralized eTMF isn't a separate configuration project layered on top of the platform, it's the default. Active Trial Management is built directly on the TMF Reference Model and includes reporting and analytics to verify TMF completeness at a glance across studies, not just within one.[1] Role-based, per-user licensing (Full Platform, Limited/Read-Only, and 3rd-Party Access) is defined once and applied consistently to anyone working across multiple trials, including CRO and site personnel. Long-Term TMF Storage doesn't charge per-GB or per-study, which matters directly for a growing portfolio — the cost of centralizing doesn't climb in lockstep with the number of active trials the way per-study or per-instance pricing often does.
Kivo customer Hyloris is a concrete example of this in practice: after moving to Kivo's unified platform, the company scaled from 10 to 20 active programs in two years without adding a proportional amount of administrative overhead — a direct illustration of what centralizing document management, permissions, and reporting is meant to make possible as a pipeline grows.
Even with one or two studies, a start-up benefits from applying a standard structure — like the TMF Reference Model's 11 zones — from day one rather than improvising. This makes it far easier to add a second or third concurrent study later without a disruptive restructuring project once the portfolio grows.
Look for storage that doesn't penalize volume with per-GB or per-study fees, supports the retention periods required for a given region (often 25+ years), and keeps documents searchable and accessible rather than archived into a cold, hard-to-query store that slows down an audit.
Yes — a well-built cloud eTMF applies role-based permissions at the study level while still managing those roles centrally, so a reviewer can be scoped to exactly the studies and document sections they need without a separate access system for each trial.
Access should be assignable by role and by need — investigator sites, monitors, sponsors, and inspectors each see only what's relevant to them — with every access event captured in an audit trail, so multi-stakeholder access doesn't come at the cost of traceability.